Is MNPR research on Rallies investment advice?

No. Rallies provides research, data, and educational context for MNPR. It does not provide personalized investment advice.

MNPR (Monopar Therapeutics Inc. Common Stock) Stock Analysis - Financials

Monopar Therapeutics Inc. Common Stock (MNPR) is a publicly traded Healthcare sector company. As of November 5, 2026, MNPR trades at $73.44 with a market cap of $469.11M and a P/E ratio of -45.14. MNPR moved +2.56% today. Year to date, MNPR is +16.69%; over the trailing twelve months it is -12.91%. Its 52-week range spans $26.06 to $124.82. Analyst consensus is strong buy with an average price target of $129.29. Rallies surfaces MNPR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What are MNPR's key financials?

MNPR financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. MNPR recently traded at $73.44. Market cap is $469.11M. P/E ratio is -45.14. Revenue is $0.

MNPR Key Metrics

Key financial metrics for MNPR
Metric	Value
Price	$73.44
Market Cap	$469.11M
P/E Ratio	-45.14
EPS	$-1.85
Dividend Yield	0.00%
52-Week High	$124.82
52-Week Low	$26.06
Volume	180.57K
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-13.72M
Gross Margin	0.00%

MNPR Analyst Consensus

7 analysts cover MNPR: 0 strong buy, 6 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $129.29.

Common questions about MNPR

What are MNPR's key financials?: MNPR financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. MNPR recently traded at $73.44. Market cap is $469.11M. P/E ratio is -45.14. Revenue is $0.
Is MNPR research on Rallies investment advice?: No. Rallies provides research, data, and educational context for MNPR. It does not provide personalized investment advice.